Managing Legal Risk in AI-Powered Pharmacovigilance
As the use of artificial intelligence (AI) in pharmacovigilance becomes increasingly scrutinized by regulators worldwide, in-house legal counsel must navigate a landscape filled with complex and challenging questions. This study explores the essential elements of managing legal risk in this evolving field.
Understanding Accountability in AI
One of the most pressing questions facing legal teams is: Who bears responsibility when algorithms fail? This issue is critical as the reliance on AI systems grows within the pharmaceutical industry. The delegation of responsibility can become murky, especially when decisions made by algorithms lead to adverse outcomes.
Auditing Black-Box Systems
Another significant challenge is auditing black-box systems. These systems, which often lack transparency, require innovative approaches to ensure compliance with regulatory standards. Legal and pharmacovigilance teams must work collaboratively to develop methodologies that can effectively audit these systems and assess their decision-making processes.
Merck’s Approach to Emerging Risks
In response to these challenges, Merck’s legal and pharmacovigilance teams have developed comprehensive strategies to manage emerging risks associated with AI usage. By focusing on collaboration and proactive risk assessment, they aim to ensure that their AI systems remain compliant with evolving regulations while safeguarding patient safety.
The dialogue surrounding the legal implications of AI in pharmacovigilance is crucial. As this technology continues to advance, so too must the frameworks that govern its use. By addressing these thorny questions early, organizations can position themselves to better navigate the complexities of AI in the pharmaceutical landscape.
